WellPoint Enters China’s Health Insurance Market
This article was originally published in PharmAsia News
WellPoint, the second largest health insurer in the U.S., has set up its representative office in Beijing to forge closer partnerships with local insurance firms and introduce its expertise to the country. WellPoint's subsidiary Anthem will develop the domestic business by establishing a client network; it has identified the government, private companies and health care providers as target customers. China's fledgling health insurance market is set to hit 120 billion yuan ($17 billion) by 2015 as the local health reform aims to make basic medical insurance available for every citizen. Seeing the huge potential, foreign health insurers such as BUPA and Swiss Reinsurance have been stepping up their activities in the country. (Click here for more - Chinese language)
You may also be interested in...
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?